About this Medicine article
Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy by Leszek Królicki; Frank Bruchertseifer; Jolanta Kunikowska; Henryk Koziara; Dariusz Pawlak; Radosław Kuliński; Rafał Rola; Adrian Merlo; Alfred Morgenstern is a Medicine article available to read on EtoBox.
## Abstract Glioblastoma is the most common and malignant primary brain tumour, with a poor prognosis. Introduction of new treatment options is critically important. The study aimed to assess the appropriateness of escalation doses and toxicity of [^225^Ac]Ac-DOTA-SP therapy. ## Material and methods A total of 21 patients (age of 43.0 ± 9.5 years), with histologically confirmed recurrent or conversion glioblastoma grade 4 following a standard therapy, have been included in the study. One to 2 intracavitary port-a-cath systems were stereotactically inserted. Patients were treated with escalation dose protocol with 10, 20 and 30 MBq per cycle totally 1–6 doses of [^225^Ac]Ac-DOTA-SP in 2-month intervals. Therapeutic response was monitored by clinical performance status and MRI imaging. ## Results Treatment was well tolerated with mostly mild temporary adverse effects (oedema, epileptic seizures, aphasia, hemiparesis) mainly in the group of patients treated with 30 MBq of [^225^Ac]Ac-DOTA-SP. Only one patient treated with 30 MBq revealed thrombopenia grade 3. There was no other grade 3 and 4 toxicity related to [^225^Ac]Ac-DOTA-treatment in all groups. The median overall survival time
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Leszek Królicki; Frank Bruchertseifer; Jolanta Kunikowska; Henryk Koziara; Dariusz Pawlak; Radosław Kuliński; Rafał Rola; Adrian Merlo; Alfred Morgenstern
- Publisher
- Springer Science and Business Media LLC
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)